2017•Urology AnnalsOpen access

One year survivor of metastatic renal cell carcinoma treated with pazopanib

FamXeng Inn, Nurzarina Ahmed, Erica Yee Hing, MohdHafidzul Jasman

Abstract

Tyrosine kinase inhibitor (TKI) and its side effects are well known. However, these are mainly descriptive, with pictorial data lacking. Here, in we report a case of metastatic renal cell carcinoma, treated with TKI, with classic side effects; supplemented with images that demonstrate the adverse effects of the drug. In addition, we discuss and demonstrate the computed tomography changes.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Pazopanib, Medicine, Renal cell carcinoma, Tyrosine-kinase inhibitor, Adverse effect, Oncology, Tyrosine kinase, Internal medicine